Search Results

Baxter and bioMérieux Announce CE Mark for NEPHROCLEAR™ CCL14 Test to Predict Persistent Severe Acute Kidney Injury

Baxter International Inc. (NYSE:BAX), a global leader in acute care, and bioMérieux (EPA:BIM), a global leader in in vitro diagnostics, today announced the CE marking of the NEPHROCLEAR™ CCL14 Test. The NEPHROCLEAR™ CCL14 Test is designed to predict persistent severe acute kidney injury (PS-AKI) and can be used to support timely clinical decision-making and care pathways.

Brainstorming for Business Solutions

Flexibility and a sense of ownership create a work environment at Baxter that drives the best possible results in our mission to save and sustain lives. With leadership support, our entrepreneurial ideas become reality. 

Unlocking a Life of Possibilities with Home Parenteral Nutrition

For 19-year-old Nutrition and Food Science student Trinity, home parenteral nutrition provides the opportunity to live an unencumbered life.  

Baxter to Present at Credit Suisse 30th Annual Virtual Healthcare Conference

Baxter International Inc. (NYSE:BAX), a leading global medical products company, will present at the Credit Suisse 30th Annual Virtual Healthcare Conference on Monday, November 8, 2021. Jay Saccaro, Baxter's chief financial officer, is scheduled to present at 8:50 a.m. Eastern Time.   The live webcast of Baxter’s presentation can be accessed at www.baxter.com and will be available for replay through November 7, 2022.

Expanding Diversity in Healthcare

Too few Black healthcare professionals in the healthcare system is one of many challenges that has a disproportionate impact on Black Americans. To help address this disparity, we're investing in students in health and sciences fields at three historically Black Colleges and Universities (HBCUs): Meharry Medical College, Morehouse School of Medicine and Tennessee State University.

Baxter Presents Critical Care Data at 34th Annual European Society of Intensive Care Medicine LIVES Congress

Baxter International Inc. (NYSE:BAX), a global leader in acute care, announced the presentation of data from three critical care studies at the 34th Annual European Society of Intensive Care Medicine (ESICM) LIVES virtual congress taking place Oct. 3 – Oct. 6, 2021. 

Global Efforts Contribute to Sustainability in Healthcare

Around the world, our teams are taking creative approaches to help protect our planet.    

Baxter to Host Third-Quarter 2021 Financial Results Conference Call for Investors

Baxter International Inc. (NYSE:BAX), a leading global medical products company, will host a conference call to discuss its third-quarter 2021 financial results on Thursday, October 28, 2021 at 7:30 a.m. Central Time. To participate in this conference call please follow this link http://www.directeventreg.com/registration/event/3534264 to pre-register for the call and receive the call information.

Dedicated to Our Patients' Needs

Our field service engineers play a vital role in installing and maintaining medical devices for customers. During the pandemic, they demonstrated an unrelenting dedication to supporting the continuation of dialysis for kidney patients in the face of mounting challenges.

Baxter Announces U.S. Approval and Launch of Ready-To-Use Cardiovascular Medicine Norepinephrine in Premix Formulation

Baxter International Inc. (NYSE:BAX), a global leader in sterile medication production and delivery, today announced the U.S. Food and Drug Administration (FDA) approval and commercial launch of premix Norepinephrine Bitartrate in 5% Dextrose Injection (norepinephrine). Norepinephrine is indicated to raise blood pressure in adult patients with severe, acute hypotension (low blood pressure).